港交所官网信息显示，靖因药业（Sirius Therapeutics）9月28日递交招股书，高盛、海通国际、汇丰为 联席保荐人。靖因药业于2021年由OrbiMed Entities及 Creacion Ventures联合创立，是一家创新生物技术 公司，聚焦新一代核酸创新疗法在心血管疾病领域的开发。 此次港股上市募资，靖因药业称，将用于核心产品SRSD107研发、关键产品SRSD216研发、关键产品 SRSD384研发、管线项目包括肝外项目研发及营运资金及业务发展用途。 值得注意的是，在业绩层面，靖因药业还没有产生收入或任何销售成本。2023年和2024年，公司期内亏 损分别为3.09亿元和3.42亿元。2025年上半年盈利3446.1万元，而去年同期则是亏损1.59亿元。扭亏为盈 的主要原因是靖因药业在与CRISPR合作中，收到了CRISPR股份带来的公允价值收益等非经常性收 益。 招股书披露的公司架构图 | | 截至12月31日止年度 | | 截至6月30日止六個月 | | | --- | --- | --- | --- | --- | | | 2023年 | 2024年 | 2024年 | 2025年 ...

Core Viewpoint - The company, Heptares Therapeutics, is gaining significant attention in the competitive biopharmaceutical industry, particularly in the fields of immune diseases and oncology, following a remarkable 51-fold increase in net profit in the first half of the year and a substantial investment from Singapore's GIC [1][6]. Investment and Partnerships - GIC increased its stake in Heptares Therapeutics by investing approximately HKD 511 million to acquire 40.22 million shares, raising its ownership from 1.62% to 6.37% [2]. - GIC, managing over USD 800 billion, is recognized for its long-term value investment strategy, and its investment in Heptares is seen as a validation of the company's technological capabilities and commercial prospects [2]. - Heptares has established multiple collaborations with major pharmaceutical companies, including three significant partnerships with AstraZeneca, which highlight its growing influence in the global biopharmaceutical sector [4][5]. Technological Advancements - Heptares has developed proprietary antibody technology platforms, such as Harbour Mice, which can generate fully human monoclonal antibodies in various forms, enhancing its drug development capabilities [3]. - The company’s innovative products, including immune cell connectors and bispecific immune cell antagonists, are positioned to provide significant therapeutic benefits in oncology and inflammatory diseases [3]. Financial Performance - In the first half of 2025, Heptares reported total revenue of approximately CNY 725 million, a year-on-year increase of 327%, and a net profit of about CNY 523 million, reflecting a 51-fold increase [6]. - The company’s cash reserves reached approximately CNY 2.291 billion, a 92% increase from the end of the previous year, indicating strong financial health [6]. - Heptares has established a sustainable business model through innovative product licensing and partnerships, with over 40 collaborations and a potential total deal value exceeding USD 10 billion [6]. Future Prospects - Heptares plans to accelerate the development of innovative product pipelines targeting both new and known targets, with several clinical trials underway [7]. - The company aims to expand its platform capabilities into immune and inflammatory disease areas, leveraging its advanced drug discovery engines [7].

Group 1 - Two companies received IPO approvals during the week, while one company, Chengdu Ruisi Environmental Technology Co., Ltd., terminated its review process on July 25 [1][2] - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. is the first company to have its IPO application accepted under the fifth set of listing standards for the Sci-Tech Innovation Board, aiming to raise 1.5 billion yuan [1] - Tainuo Maibo reported revenues of 4.34 million yuan in 2022, with losses of 429 million yuan, 446 million yuan, 515 million yuan, and 177 million yuan in the same period [1] Group 2 - High Ling Chen Jun, a private equity fund manager, holds a 3.94% stake in Tainuo Maibo, having invested in the company before its IPO application [2] - Delijia Transmission Technology (Jiangsu) Co., Ltd. and Changjiang Sanxing Energy Technology Co., Ltd. also received IPO approvals, with the former's application taking seven months from acceptance to approval [2] - Ruisi Environmental's main revenue source, the denitration reducing agent preparation system, accounted for over 71% of its main business income in recent years, indicating potential market expansion risks [3]

Core Viewpoint - The chairman and general manager of Maiwei Biotech, Liu Datao, is under investigation by the China Securities Regulatory Commission (CSRC) for suspected short-term trading, which may impact the company's operations and market confidence [1][2][10]. Company Overview - Maiwei Biotech was founded in May 2017 and went public on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 18, 2022, focusing on innovative biopharmaceuticals across various therapeutic areas [6]. - The company has experienced significant revenue growth but has faced substantial net losses since its listing [7]. Financial Performance - In 2022, Maiwei Biotech reported revenue of 27.73 million yuan, a year-on-year increase of 70.88%, but incurred a net loss of 955 million yuan [7]. - Revenue rose to 128 million yuan in 2023, a 361.03% increase, yet the net loss expanded to 1.053 billion yuan [7]. - For 2024, revenue further increased to 200 million yuan, a 56.28% growth, but the net loss remained high at 1.044 billion yuan [7]. Cost and Investment - The company attributes revenue growth to successful market expansion and increased sales of its core products, but rising operating costs and high R&D expenses have compressed profit margins [8]. - R&D expenses were reported at 759 million yuan in 2022, 836 million yuan in 2023, and 783 million yuan in 2024, indicating sustained high investment levels [8]. Market Sentiment - Maiwei Biotech's stock price has been declining, with a cumulative drop of over 12% from April 25 to May 9 [5]. - The ongoing investigation into the chairman may further dampen market confidence and complicate the company's plans for an H-share listing in Hong Kong [10].